Fisetin is a plant flavonoid — found most abundantly in strawberries — that has drawn serious scientific interest as a natural senolytic: a compound that selectively clears worn-out “senescent” cells linked to ageing. The animal data are genuinely promising, including lifespan extension in old mice. But the human evidence is still early, the doses used in research are far beyond anything you could eat, and fisetin’s poor absorption makes real-world results hard to predict. Here’s what the science actually supports.
What is fisetin?
Fisetin is a polyphenol in the flavonoid family, the same broad class as quercetin. It occurs naturally in a range of fruits and vegetables and has long been studied as an antioxidant and anti-inflammatory compound. Its modern reputation, though, rests on a more specific property discovered relatively recently: the ability to act as a senolytic.
The senolytic mechanism: clearing “zombie” cells
As we age, cells accumulate that have stopped dividing but refuse to die — senescent cells, often nicknamed “zombie” cells. Rather than quietly disappearing, they linger and secrete a cocktail of inflammatory signals known as the senescence-associated secretory phenotype (SASP), which damages surrounding tissue and is thought to help drive many features of ageing.
Senolytics are compounds that selectively nudge these cells into dying off while leaving healthy cells intact. Fisetin appears to do exactly that. A frequently cited 2018 study in EBioMedicine screened a panel of flavonoids and identified fisetin as the most potent senolytic among them. In aged and prematurely-ageing mice, intermittent fisetin reduced markers of senescence across multiple tissues — consistent with a “hit-and-run” mechanism, where short bursts of treatment clear senescent cells that then take time to rebuild. For the broader concept, see our explainers on how senolytics clear zombie cells and why this field has generated so much excitement.
Most striking, in that study fisetin given to normal mice late in life reduced age-related pathology and extended both median and maximum lifespan — one of the clearer demonstrations that a senolytic can improve lifespan even when started in old age.
The human trial landscape: promising but early
This is where expectations need tempering. The lifespan result above is in mice. In humans, fisetin is being tested, but the programme is early and the published outcomes are limited.
- Researchers at the Mayo Clinic have run and registered several human studies of fisetin as a senolytic, including trials in frailty, osteoarthritis and other age-related conditions.
- The AFFIRM trial (Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Adults) is among the efforts examining whether intermittent fisetin can improve function in older people.
- Early human dosing work has reported no serious adverse events, which is reassuring on safety — but safety is not the same as proven benefit.
It’s worth being clear-eyed about where fisetin sits relative to its better-studied cousin. The combination of dasatinib (a prescription drug) and quercetin is currently the senolytic regimen with the most human evidence for actually clearing senescent cells, having shown effects in clinical trials. Fisetin is promising and appealing because it’s a naturally occurring compound, but it has not yet matched that level of human validation. Treat current human fisetin data as hypothesis-testing, not proof of a longevity effect.
Food sources: real, but not at research doses
Fisetin is genuinely present in everyday foods. Strawberries contain the highest concentrations by a wide margin, with much smaller amounts in apples, persimmons, grapes, onions and cucumbers.
The catch is scale. The amounts used in senolytic research are orders of magnitude higher than what any realistic diet delivers — you cannot eat enough strawberries to reach a senolytic dose. That doesn’t make fisetin-rich foods pointless; they’re part of a healthy, polyphenol-rich diet. But eating strawberries and taking a senolytic dose of fisetin are two entirely different things, and only the former has a track record of being safe and sensible.
Dosing patterns discussed in research
A defining feature of fisetin’s senolytic use is that it is intermittent, not daily. Reflecting the “hit-and-run” model, research protocols have typically used short, high-dose pulses — for example, a high dose given on a small number of consecutive days, repeated only periodically — rather than continuous supplementation. Some human studies have used doses in the region of 20 mg per kilogram of body weight for two consecutive days.
This matters for anyone reading about fisetin: the research model is a periodic clearance pulse, which is conceptually very different from taking a daily antioxidant. None of this is an established, regulator-approved protocol, and optimal dosing in humans remains unsettled.
The bioavailability caveat
Fisetin’s biggest practical weakness is that it is poorly absorbed. It has low aqueous solubility and is rapidly metabolised, so a large share of an oral dose never reaches the bloodstream in active form. Taking it with fat is thought to improve uptake, and manufacturers have developed novel formulations (such as liposomal preparations) aimed at boosting absorption.
The consequence is uncertainty: the same labelled dose may behave very differently depending on formulation and whether it’s taken with food, which complicates both research and self-experimentation. It also means that encouraging mouse data can’t be translated into a confident human dose.
What a cautious approach looks like
If fisetin interests you, it helps to separate two very different activities. Eating fisetin-rich foods as part of a varied, plant-forward diet is uncontroversial and sensible — strawberries and the rest bring fibre, vitamins and a spread of polyphenols regardless of any senolytic effect. Taking high, intermittent senolytic doses to clear senescent cells is a genuine experiment, one where the human payoff is unproven, the right dose is unsettled and absorption varies with formulation.
That distinction also guards against a common error in longevity circles: assuming that because a compound is “natural” and sold without prescription, it must be both safe and effective at any dose. Senolytics are pharmacologically active by design — they push cells towards death — and clearing cells indiscriminately or too often is not obviously benign. The research model’s periodic, short pulses exist for a reason. Anyone experimenting is wise to do so with medical oversight, to be honest that they’re ahead of the evidence, and to keep the proven fundamentals — training, sleep, diet — as the foundation rather than the afterthought.
Frequently asked questions
Is fisetin a proven anti-ageing supplement?
No. Fisetin has strong senolytic data in mice, including lifespan extension, but human trials are early-stage and have not yet demonstrated longevity or healthspan benefits. It remains experimental.
Can I get enough fisetin from strawberries?
Not at the doses used in research. Strawberries are the richest dietary source, but senolytic study doses are far higher than any diet can provide. Eating fisetin-rich foods is healthy; it is not the same as taking a senolytic dose.
How is fisetin dosed in studies?
Typically as intermittent high-dose pulses — for instance a high dose on two consecutive days, repeated periodically — reflecting a “hit-and-run” senolytic model rather than daily use. There is no regulator-approved longevity protocol.
Why does fisetin’s poor bioavailability matter?
Because it has low solubility and is cleared quickly, much of an oral dose doesn’t reach the bloodstream in active form, making real-world effects hard to predict and animal doses hard to translate to people.
The takeaway
Fisetin is one of the more exciting natural candidates in the senolytic field: a food-derived flavonoid that clears senescent cells and extended lifespan in old mice, with early human safety data looking acceptable. But “exciting in mice” and “early in humans” are precisely where it stands — the human evidence hasn’t yet shown a longevity benefit, dietary amounts fall far short of research doses, and poor absorption adds real uncertainty. Enjoy strawberries freely; treat senolytic-dose fisetin as a promising experiment still awaiting its human verdict, and best approached with medical input rather than guesswork.